We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares

Delisted

FUSN was delisted on the 3rd of June, 2024.

29 hedge funds and large institutions have $304M invested in Fusion Pharmaceuticals Inc. Common Shares in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

37% less capital invested

Capital invested by funds: $483M → $304M (-$179M)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

43% less funds holding

Funds holding: 5129 (-22)

81% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 27

Holders
29
Holders Change
-22
Holders Change %
-43.14%
% of All Funds
0.59%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
5
Increased
5
Reduced
8
Closed
27
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
JJIJ
1
Johnson & Johnson Innovation - JJDC
New Jersey
$44.1M
ASP
2
Adams Street Partners
Illinois
$40M
O
3
OrbiMed
New York
$38.8M
Fidelity Investments
4
Fidelity Investments
Massachusetts
$37.6M +$1.17M +85,805 +3%
Canada Pension Plan Investment Board
5
Canada Pension Plan Investment Board
Ontario, Canada
$37.5M
TGHSA
6
TPG Group Holdings (SBS) Advisors
Texas
$30.7M
PA
7
Perceptive Advisors
New York
$26.9M
DM
8
Deerfield Management
New York
$11.7M -$3.89M -284,954 -23%
RSCM
9
Rock Springs Capital Management
Maryland
$11.4M +$144K +10,500 +1%
Federated Hermes
10
Federated Hermes
Pennsylvania
$6.13M +$2.6M +190,000 +59%
BlackRock
11
BlackRock
New York
$5.53M +$91.9K +6,727 +1%
CCP
12
Clough Capital Partners
Massachusetts
$4.84M
FCM
13
Farallon Capital Management
California
$2.25M -$853K -62,400 -25%
Victory Capital Management
14
Victory Capital Management
Texas
$1.82M -$439K -32,117 -17%
WP
15
Woodline Partners
California
$915K -$600K -43,907 -37%
Alyeska Investment Group
16
Alyeska Investment Group
Illinois
$909K
CCM
17
CAAS Capital Management
New York
$702K -$21.9K -1,602 -3%
Norges Bank
18
Norges Bank
Norway
$601K
SFI
19
Susquehanna Fundamental Investments
Pennsylvania
$478K +$543K +39,739 New
AllianceBernstein
20
AllianceBernstein
Tennessee
$444K -$520K -38,058 -51%
Morgan Stanley
21
Morgan Stanley
New York
$321K -$8.81M -644,725 -96%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$277K +$316K +23,089 New
HF
23
HRT Financial
New York
$121K +$138K +10,068 New
Bank of Montreal
24
Bank of Montreal
Ontario, Canada
$64K +$74.7K +5,465 New
AA
25
AlphaCentric Advisors
Puerto Rico
$46K +$27.3K +2,000 +111%

FUSN Hedge Fund Activity: Q3 2020 in Review

29 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q3 2020, worth a combined $304M — down 37% from $483M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of FUSN and 5 opened new positions — a net loss of 22 holders — while 8 trimmed existing stakes and 5 added.

The largest buyer was Federated Hermes, adding an estimated $2.6M. The largest seller was Morgan Stanley, cutting an estimated $8.81M.

  • 29 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q3 2020, down from 51 in Q2 2020.
  • Funds reported $304M of Fusion Pharmaceuticals Inc. Common Shares stock for Q3 2020, down 37% quarter-over-quarter.
  • 5 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q3 2020 and 27 closed out, a net change of -22 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q3 2020 was Federated Hermes, an estimated $2.6M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q3 2020 was Morgan Stanley, an estimated $8.81M sold.

Based on aggregated 13F filings for Q3 2020.